Contineum Therapeutics CTNM Income Statement (2023-2026)

NASDAQ CTNM
$17.05 -0.52 (-2.96%)
As of: Sep 4, 2026 · 12:42 PM EDT
Reported Financials

Contineum Therapeutics Quarterly Income Statement

Periods 14 quarters
Latest Jun 2026

Contineum Therapeutics reported net income of -$15.47M for the quarter ended Jun 2026. This income statement covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.) 9.11M9.11M9.11M9.11M9.11M25.72M25.73M25.85M25.87M25.90M29.18M37.32M37.34M37.47M
Revenue & cost
Revenue 50.00M
Operating items
Research & DevelopmentR&D 3.63M9.46M6.50M8.01M7.78M7.90M9.73M13.02M13.71M14.06M10.99M12.76M11.65M12.70M
Selling, General & AdministrativeSG&A 1.48M1.60M1.57M1.66M2.15M3.04M3.25M4.03M4.40M3.84M3.94M4.36M5.26M4.73M
Operating ExpensesOpex 5.12M11.06M8.07M9.68M9.93M10.94M12.97M17.05M18.11M17.90M14.93M17.11M16.90M17.43M
Operating IncomeOp. Inc -5.12M38.94M-8.07M-9.68M-9.93M-10.94M-12.97M-17.05M-18.11M-17.90M-14.93M-17.11M-16.90M-17.43M
EBIT -5.12M38.94M-8.07M-9.68M-9.93M-10.94M-12.97M-17.05M-18.11M-17.90M-14.93M-17.11M-16.90M-17.43M
Non-operating items
Non Operating Interest Expenses 0.09M0.12M
Interest & Investment IncomeInt & Inv Inc 0.07M-0.06M1.74M1.79M-0.17M-0.07M2.74M2.53M0.10M2.03M1.96M2.01M-0.51M2.34M
Other Non Operating IncomeOther Non Op Inc. -0.02M-0.08M-0.04M1.27M-0.01M-0.08M-0.03M-0.05M-0.13M-0.17M0.18M-0.05M-0.06M-0.07M
Non Operating IncomeNon Op. Inc. 0.29M3.36M1.70M1.75M1.51M1.94M2.71M2.48M2.12M1.86M2.41M1.96M2.45M2.27M
Net income details
EBT -4.82M42.30M-6.37M-7.93M-8.42M-9.01M-10.27M-14.56M-18.01M-15.87M-12.97M-15.11M-17.42M-15.09M
Tax ProvisionsTaxes 0.73M-0.12M4.28M-8.88M
Profit After TaxPAT -4.82M41.56M-6.28M-7.58M-8.42M-9.01M-10.27M-14.60M-15.99M-16.06M-12.80M-15.18M-14.46M-15.47M
Income from Continuing OperationsIncome (Continuing) -4.82M41.57M-6.25M-12.21M-8.42M-9.01M-10.27M-5.68M-18.01M-15.87M-12.97M-15.11M-17.42M-15.09M
Consolidated Net IncomeConsol Net Inc. -4.82M41.57M-6.25M-12.21M-8.42M-9.01M-10.27M-5.68M-18.01M-15.87M-12.97M-15.11M-17.42M-15.09M
Income towards Parent CompanyParent Net Inc -4.82M41.57M-6.25M-12.21M-8.42M-9.01M-10.27M-5.68M-18.01M-15.87M-12.97M-15.11M-17.42M-15.09M
Net Income towards Common StockholdersNet Income -4.82M41.57M-6.25M-12.21M-8.42M-9.01M-10.27M-5.68M-15.99M-16.04M-12.79M-15.11M-17.42M-15.09M
Additional items
EPS (Basic) -2.1218.11-2.69-5.28-3.55-0.39-0.40-0.29-0.62-0.62-0.45-0.55-0.47-0.40
EPS (Diluted) -2.1211.84-2.69-3.59-3.55-0.39-0.40-0.29-0.62-0.62-0.49-0.55-0.47-0.40
Shares Outstanding 2.28M2.30M2.33M2.31M2.37M23.36M25.73M19.35M25.87M25.90M28.12M27.70M37.34M37.47M
Shares Outstanding (Diluted)Shares Outstanding (Dil.) 2.28M3.51M2.32M3.40M2.37M23.36M25.73M19.35M25.87M25.90M25.90M27.70M37.34M37.47M
EBITDA -5.12M38.94M-8.07M-9.68M-9.93M-10.94M-12.97M-17.05M-18.11M-17.90M-14.93M-17.11M-16.90M-17.43M
Interest ExpensesInt Expense 0.09M0.12M
Tax Rate 1.721.85-53.9161.00